Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

lncRNAs as New Biomarkers in Systemic Lupus Erythematosus: A Prospective Study


Affiliations
1 Medical Biochemistry and Molecular Biology Department, Cairo University, Egypt
2 Rheumatology and Rehabilitation Department, Cairo University, Egypt
     

   Subscribe/Renew Journal


Aim: To investigate serum levels of two Immune-related functional lncRNAs, growth arrest-specific transcript 5 (GAS5) and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), in Egyptian patients with SLE and to evaluate their relationship with disease activity.

Method: The present study was a case-control study that was carried out on 39 patients with SLE and 46 age and sex-matched healthy controls. The expression levels of GAS5 and MALAT1 were measured using by real-time polymerase chain reaction (PCR).

Results: There were statistically significant differences between cases and controls in GAS5 (p <0.001) and MALAT1 expression (p <0.01). The mean GAS5 was significantly higher in the control; while the mean MALATI expression was significantly higher in SLE patients. The ROC curve revealed that GAS5 was a good discriminant with AUC 0.849 with sensitivity 93.5% and specificity 74.3%. Moreover, MALAT1 was a good discriminant to differentiate cases from controls with AUC 0.3 with 95% CI (0.162 - 0.438), the most suitable cut-off point was ≥ 2.1 with Sensitivity 93.5% and Specificity 72.5%.

Conclusion: GAS5 and MALAT1 may serve as potential biomarkers for the diagnosis and monitoring of the SLE, both lnRNAs exhibited a good diagnostic accuracy to discriminate between SLE patients and healthy controls.


Keywords

lncRNAs, Systematic Lupus, Biomarker, Diagnostic Accuracy.
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 498

PDF Views: 0




  • lncRNAs as New Biomarkers in Systemic Lupus Erythematosus: A Prospective Study

Abstract Views: 498  |  PDF Views: 0

Authors

Olfat Gamil Shaker
Medical Biochemistry and Molecular Biology Department, Cairo University, Egypt
Yasser Hussein Nassar
Medical Biochemistry and Molecular Biology Department, Cairo University, Egypt
Tamer Atef Gheta
Medical Biochemistry and Molecular Biology Department, Cairo University, Egypt
Randa Mohamed Essameldin Moussa Erfan
Rheumatology and Rehabilitation Department, Cairo University, Egypt

Abstract


Aim: To investigate serum levels of two Immune-related functional lncRNAs, growth arrest-specific transcript 5 (GAS5) and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), in Egyptian patients with SLE and to evaluate their relationship with disease activity.

Method: The present study was a case-control study that was carried out on 39 patients with SLE and 46 age and sex-matched healthy controls. The expression levels of GAS5 and MALAT1 were measured using by real-time polymerase chain reaction (PCR).

Results: There were statistically significant differences between cases and controls in GAS5 (p <0.001) and MALAT1 expression (p <0.01). The mean GAS5 was significantly higher in the control; while the mean MALATI expression was significantly higher in SLE patients. The ROC curve revealed that GAS5 was a good discriminant with AUC 0.849 with sensitivity 93.5% and specificity 74.3%. Moreover, MALAT1 was a good discriminant to differentiate cases from controls with AUC 0.3 with 95% CI (0.162 - 0.438), the most suitable cut-off point was ≥ 2.1 with Sensitivity 93.5% and Specificity 72.5%.

Conclusion: GAS5 and MALAT1 may serve as potential biomarkers for the diagnosis and monitoring of the SLE, both lnRNAs exhibited a good diagnostic accuracy to discriminate between SLE patients and healthy controls.


Keywords


lncRNAs, Systematic Lupus, Biomarker, Diagnostic Accuracy.



DOI: https://doi.org/10.37506/v11%2Fi2%2F2020%2Fijphrd%2F195238